Upstream announces the close of a convertible note round that sought a minimum of NZ$1.2m and a target of NZ$1.8m led by Pacific Channel.
Upstream closes NZ$2.3m financing
Upstream was overwhelmed by the response and received investments totalling NZ$2,243,000, representing oversubscriptions of NZ$443,000. Funds raised in the convertible note will be used to continue validation and development of Upstream tests to detect those at risk of heart attack, to progress work on preparing for future clinical studies.
Detecting at-risk heart attack patients, a step closer with $2m investment
Upstream Medical Technologies, a leading deep-tech company focused on developing innovative solutions for heart disease, announced today that it has closed a significant capital round to further advance its frontline diagnostic tests for cardiac diseases.
Upstream commences testing Marker C on the APACE cohort
The next phase of development is now underway, with the commencement of testing Marker C on the APACE cohort.